ArticleACS omega2026
Structure-Guided SOCS3 Peptidomimetics: Design and Functional Characterization.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Suppressor of Cytokine Signaling 3 (SOCS3) is a pivotal negative regulator of the JAK/STAT pathway, and its loss or silencing is frequently associated with hyperactivated STAT3 signaling in aggressive cancers, including Triple-Negative Breast Cancer (TNBC). In this study, we present the rational design, biophysical characterization, and cellular evaluation of novel SOCS3-derived peptidomimetics that incorporate a hitherto unexploited structural determinant of the SOCS3/JAK2/Gp130 interface: the BC loop. The synthesis of individual and chimeric peptides was guided by structural analysis of the ternary complex, which combined the KIR/ESS regions with a stabilized BC loop. The results of the study revealed that the chimeric construct, KIRESS BC loop-chim, exhibited markedly improved affinity for JAK2 (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.